Some posters seem to dismiss income from CC Pharma because it is primarily a distributor of pharmaceuticals AT THIS TIME. It is a distinction without a difference. Aphira's plan is to use CC to distribute it's MJ products throughout Germany and the the rest of the EU, as more and more countries legalize medical marijuana. The income generated by CC Pharma will remain a substantial portion of APHA's revenues and profits for years to come. It was one of the best investments made by any MJ company in the past 2 years.
Aphria Completes Acquisition of CC Pharma, Leading German Pharmaceutical and Medical Cannabis Distributor
Jan 09, 2019, 03:00 ET
LEAMINGTON, ON, Jan. 9, 2019 /PRNewswire/ - Aphria Inc. ("Aphria" or the "Company") (TSX: APHA andNYSE: APHA) today announced that it had completed its previously announced acquisition of CC Pharma GmbH ("CC Pharma"), a leading distributor of pharmaceutical products, including medical cannabis, to more than 13,000 pharmacies in Germany, as well as throughout Europe. The Company continues to strengthen its end-to-end cannabis operations and infrastructure in Germany.
"As one of the most promising medical cannabis markets in the world, Germany is a top strategic priority for Aphria. With today's acquisition of CC Pharma, Aphria is creating a German and ultimately pan-European platform that brings together demand, supply and distribution." said Vic Neufeld, CEO of Aphria. "We're excited to welcome the CC Pharma team and the pharmacists they serve to the Aphria family."
Dr. Manfred Ziegler, Managing Director of CC Pharma, added, "We're thrilled to be joining forces with Aphria. Access to Aphria's innovative products creates significant opportunities for CC Pharma's customers to experience more medical cannabis treatment options."
CC Pharma is a leading importer and distributor of EU-pharmaceuticals for the German market. Founded in 1999, today it has over 230 employees and offices in Germany, Denmark, Poland and the Czech Republic. CC Pharma holds 318 active German national pharmaceutical licenses and 692 active EU pharmaceutical licenses, and also operates a production, repackaging and labeling facility at its headquarters in Densborn, Germany. During 2018, CC Pharma generated revenue of approximately €262 million, with EBITDA of approximately €10.5 million.
"Through a series of deliberate and strategic partnerships, investments and appointments over the past 18 months, Aphria is a front runner in the German medical cannabis market," said Hendrik Knopp, Managing Director of Aphria Germany. "CC Pharma's shared values, deep relationships and local regulatory and logistical experience are a perfect complement to Aphria's expertise. One of our first steps will be to create a new division of CC Pharma dedicated to medical cannabis."
In addition to today's acquisition of CC Pharma, other previously announced strategic milestones for Aphria and its wholly owned subsidiaries in Germany include:
A significant supply agreement to provide CC Pharma approximately 1,200 kilograms of medical cannabis products, exported from Canada and Denmark to Germany.
A 2018 investment in Berlin-based Schöneberg Hospital, a first step in Aphria's plans to build and operate pain treatment centres throughout Germany.
The construction of a state-of-the-art, GMP certified cannabis vaults (5,000 kg storage capacity), in Bad Bramstedt, Germany, to be completed by late spring 2019.
The start of construction of a Research and Development indoor growing facility in Neumünster, Germany, in preparation for in-country cultivation.
Aphria paid €18.92 million in cash to the former shareholders of CC Pharma with an earn-out multiple on future EBITDA of up to another €23.5 million, if certain performance milestones are met.
We Have A Good Thing Growing
